Apellis Pharmaceuticals Stock Probability of Future Stock Price Finishing Under 23.28
| APLS Stock | USD 34.64 0.38 1.09% |
Apellis |
Apellis Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Apellis Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Apellis Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies |
Apellis Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Apellis Stock often depends not only on the future outlook of the current and potential Apellis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Apellis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 118.7 M | |
| Cash And Short Term Investments | 352.3 M |
Apellis Pharmaceuticals Technical Analysis
Apellis Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Apellis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Apellis Pharmaceuticals. In general, you should focus on analyzing Apellis Stock price patterns and their correlations with different microeconomic environments and drivers.
Apellis Pharmaceuticals Predictive Forecast Models
Apellis Pharmaceuticals' time-series forecasting models is one of many Apellis Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Apellis Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Apellis Pharmaceuticals
Checking the ongoing alerts about Apellis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Apellis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.